165 related articles for article (PubMed ID: 23285069)
1. Efficacy of ciprofloxacin-gentamicin combination therapy in murine bubonic plague.
Lemaître N; Ricard I; Pradel E; Foligné B; Courcol R; Simonet M; Sebbane F
PLoS One; 2012; 7(12):e52503. PubMed ID: 23285069
[TBL] [Abstract][Full Text] [Related]
2. In vitro efficacy of antibiotics commonly used to treat human plague against intracellular Yersinia pestis.
Wendte JM; Ponnusamy D; Reiber D; Blair JL; Clinkenbeard KD
Antimicrob Agents Chemother; 2011 Aug; 55(8):3752-7. PubMed ID: 21628541
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of doxycycline and ciprofloxacin against experimental Yersinia pestis infection.
Russell P; Eley SM; Green M; Stagg AJ; Taylor RR; Nelson M; Beedham RJ; Bell DL; Rogers D; Whittington D; Titball RW
J Antimicrob Chemother; 1998 Feb; 41(2):301-5. PubMed ID: 9533478
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of the latest fluoroquinolones against experimental Yersinia pestis.
Steward J; Lever MS; Russell P; Beedham RJ; Stagg AJ; Taylor RR; Brooks TJ
Int J Antimicrob Agents; 2004 Dec; 24(6):609-12. PubMed ID: 15555886
[TBL] [Abstract][Full Text] [Related]
5.
Steenbergen J; Tanaka SK; Miller LL; Halasohoris SA; Hershfield JR
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28223382
[TBL] [Abstract][Full Text] [Related]
6. Doxycycline or ciprofloxacin prophylaxis and therapy against experimental Yersinia pestis infection in mice.
Russell P; Eley SM; Bell DL; Manchee RJ; Titball RW
J Antimicrob Chemother; 1996 Apr; 37(4):769-74. PubMed ID: 8722542
[TBL] [Abstract][Full Text] [Related]
7. Comparison of 2 antibiotics that inhibit protein synthesis for the treatment of infection with Yersinia pestis delivered by aerosol in a mouse model of pneumonic plague.
Heine HS; Louie A; Sorgel F; Bassett J; Miller L; Sullivan LJ; Kinzig-Schippers M; Drusano GL
J Infect Dis; 2007 Sep; 196(5):782-7. PubMed ID: 17674322
[TBL] [Abstract][Full Text] [Related]
8. Transcriptomic and innate immune responses to Yersinia pestis in the lymph node during bubonic plague.
Comer JE; Sturdevant DE; Carmody AB; Virtaneva K; Gardner D; Long D; Rosenke R; Porcella SF; Hinnebusch BJ
Infect Immun; 2010 Dec; 78(12):5086-98. PubMed ID: 20876291
[TBL] [Abstract][Full Text] [Related]
9. Antibody Opsonization Enhances Early Interactions between Yersinia pestis and Neutrophils in the Skin and Draining Lymph Node in a Mouse Model of Bubonic Plague.
Shannon JG; Hinnebusch BJ
Infect Immun; 2020 Dec; 89(1):. PubMed ID: 33077628
[TBL] [Abstract][Full Text] [Related]
10. Cethromycin-mediated protection against the plague pathogen Yersinia pestis in a rat model of infection and comparison with levofloxacin.
Rosenzweig JA; Brackman SM; Kirtley ML; Sha J; Erova TE; Yeager LA; Peterson JW; Xu ZQ; Chopra AK
Antimicrob Agents Chemother; 2011 Nov; 55(11):5034-42. PubMed ID: 21859946
[TBL] [Abstract][Full Text] [Related]
11. [Antibiotics of the aminoglycoside group (gentamicin, sisomicin and amikacin) in the prevention and treatment of experimental plague].
Shcherbaniuk AI; Makarovskaia LN; Bugaeva OK; Kasatkina IV
Antibiot Khimioter; 1992 May; 37(5):30-1. PubMed ID: 1417325
[TBL] [Abstract][Full Text] [Related]
12. Yersinia pestis YopJ suppresses tumor necrosis factor alpha induction and contributes to apoptosis of immune cells in the lymph node but is not required for virulence in a rat model of bubonic plague.
Lemaître N; Sebbane F; Long D; Hinnebusch BJ
Infect Immun; 2006 Sep; 74(9):5126-31. PubMed ID: 16926404
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of imipenem for prophylaxis and therapy of Yersinia pestis delivered by aerosol in a mouse model of pneumonic plague.
Heine HS; Louie A; Adamovicz JJ; Amemiya K; Fast RL; Miller L; Opal SM; Palardy J; Parejo NA; Sörgel F; Kinzig-Schippers M; Drusano GL
Antimicrob Agents Chemother; 2014 Jun; 58(6):3276-84. PubMed ID: 24687492
[TBL] [Abstract][Full Text] [Related]
14. Assessment of a fluoroquinolone, three beta-lactams, two aminoglycosides, and a cycline in treatment of murine Yersinia pestis infection.
Bonacorsi SP; Scavizzi MR; Guiyoule A; Amouroux JH; Carniel E
Antimicrob Agents Chemother; 1994 Mar; 38(3):481-6. PubMed ID: 8203841
[TBL] [Abstract][Full Text] [Related]
15. Role of the Yersinia pestis Ail protein in preventing a protective polymorphonuclear leukocyte response during bubonic plague.
Hinnebusch BJ; Jarrett CO; Callison JA; Gardner D; Buchanan SK; Plano GV
Infect Immun; 2011 Dec; 79(12):4984-9. PubMed ID: 21969002
[TBL] [Abstract][Full Text] [Related]
16. In vitro activities of 14 antibiotics against 100 human isolates of Yersinia pestis from a southern African plague focus.
Frean JA; Arntzen L; Capper T; Bryskier A; Klugman KP
Antimicrob Agents Chemother; 1996 Nov; 40(11):2646-7. PubMed ID: 8913481
[TBL] [Abstract][Full Text] [Related]
17. Imaging of bubonic plague dynamics by in vivo tracking of bioluminescent Yersinia pestis.
Nham T; Filali S; Danne C; Derbise A; Carniel E
PLoS One; 2012; 7(4):e34714. PubMed ID: 22496846
[TBL] [Abstract][Full Text] [Related]
18. Use of an in vitro pharmacodynamic model to derive a moxifloxacin regimen that optimizes kill of Yersinia pestis and prevents emergence of resistance.
Louie A; Heine HS; VanScoy B; Eichas A; Files K; Fikes S; Brown DL; Liu W; Kinzig-Schippers M; Sörgel F; Drusano GL
Antimicrob Agents Chemother; 2011 Feb; 55(2):822-30. PubMed ID: 21115791
[TBL] [Abstract][Full Text] [Related]
19. [Yersinia pestis and plague - an update].
Stock I
Med Monatsschr Pharm; 2014 Dec; 37(12):441-8; quiz 449. PubMed ID: 25643450
[TBL] [Abstract][Full Text] [Related]
20. Braun lipoprotein (Lpp) contributes to virulence of yersiniae: potential role of Lpp in inducing bubonic and pneumonic plague.
Sha J; Agar SL; Baze WB; Olano JP; Fadl AA; Erova TE; Wang S; Foltz SM; Suarez G; Motin VL; Chauhan S; Klimpel GR; Peterson JW; Chopra AK
Infect Immun; 2008 Apr; 76(4):1390-409. PubMed ID: 18227160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
